

SUPPORT FOR THE AMENDMENTS

Claims 1-12 have been amended.

Claims 13-18 have been added.

Support for the amendment to Claims 1-12 is provided by the corresponding original claims. Support for new Claims 13-18 is provided by the specification as originally filed at, for example, page 28, line 11 to page 29, line 13.

No new matter has been presented by the present amendments.

REMARKS

Claims 1-18 are pending in the present application.

Applicants acknowledge Examiner Chang's indication that Claims 5-9 are free from the art and allowable (paragraph 4 on page 3 of the Office Action mailed June 17, 2010). Reconsideration of the outstanding rejections is requested in view of the amendments herein.

The rejection of Claims 1-9 and 12 under 35 U.S.C. §112, first paragraph, and the rejection of Claim 12 under 35 U.S.C. §112, second paragraph, are believed to be obviated by amendment.

Applicants make no statement with respect to the propriety of these grounds of rejection and in no way acquiesce to the same. Solely to expedite examination of this application, Applicants have deleted the objected to language in Claims 1-12 and have rewritten Claim 12 to be drawn to a pharmaceutical composition. Accordingly, these rejections are believed to be moot.

Withdrawal of these grounds of rejection is requested.

Applicants submit that the present application is in condition for allowance. Early notification to this effect is respectfully requested.


Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, L.L.P.
Richard L. Treanor, Ph.D.

Customer Number

22850

Tel: (703) 413-3000
Fax: (703) 413 -2220
(OSMMN 03/06)



Vincent K. Shier, Ph.D.
Registration No. 50,552